Finally an effective treatment for allergic diseases!. Cet article n’est pas disponible.
Langue : anglais
Edité par Our Knowledge Publishing, 2023
- Livre broché
- Neuf

Vendeur : preigu, Osnabrück, Allemagnepreigu
Vendeur avec une évaluation de 5 étoiles
Vendeur AbeBooks depuis 5 août 2024
Indisponible
Livre broché
Etat: Neuf
EUR 39,45
A propos de cet article
Finally an effective treatment for allergic diseases! | Selsabil Daboussi (u. a.) | Taschenbuch | Englisch | 2023 | Our Knowledge Publishing | EAN 9786205730119 | Verantwortliche Person für die EU: SIA OmniScriptum Publishing, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.
N° de réf. du vendeur 126635329
- Titre
- Finally an effective treatment for allergic diseases!
- Auteur
- Selsabil Daboussi (u. a.)
- Éditeur
- Our Knowledge Publishing
- Année de publication
- 2023
- État de l'article
- Neu
- Reliure
- Taschenbuch
- Langue
- anglais
- ISBN à 10 chiffres
- 6205730111
- ISBN à 13 chiffres
- 9786205730119
- Poids de l'article
- 107 grammes
- Dimensions
- 220 x 150 x 4 mm
- Catalogues du vendeur
- Bücher
Allergic diseases are ranked fourth in terms of frequency in the WHO (World Health Organization) classification of world diseases, and they can manifest themselves through multiple clinical presentations, including rhinitis. Sublingual allergen immunotherapy to grass pollen is mainly intended for patients with allergic rhinitis associated or not with mild or moderate asthma or allergic conjunctivitis, and who have not responded to symptomatic treatment.The aim of allergen immunotherapy is to administer regular and increasing doses of allergenic extracts, to modify the immune response and to generate a lasting tolerance of the specific antigen. The first stage is characterized by the desensitization of basophils and mast cells, thus decreasing the affinity to immunoglobulin E (IgE). This desensitization is followed by T cell tolerance. During ITA, there is a progressive decrease in IgE levels and an increase in antigen-specific immunoglobulin G4 (IgG4) blockers.
« Synopsis » peut appartenir à une autre édition de cet ouvrage.